Janssen EMEA Receives Conditional Marketing Authorisation for RYBREVANT® ▼ (amivantamab), the First Treatment Approved for Patients with Advanced NonSmall Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutations After Failure of Platinum-Based Therapy | Johnson & Johnson

Janssen EMEA Receives Conditional Marketing Authorisation for RYBREVANT® ▼ (amivantamab), the First Treatment Approved for Patients with Advanced NonSmall Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutations After Failure of Platinum-Based Therapy

12/10/2021

DownloadPDF 215 KB

Multimedia Files:

Questions? Please contact us:

investor-relations@its.jnj.com